ArticlePloS one2020
Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- Pooled it
- Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment.The journal of prevention of Alzheimer's disease · 2024Trial
- Longitudinal Trajectories of the Cognitive Function Index in the A4 Study.The journal of prevention of Alzheimer's disease · 2024Trial
- The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: A vignette-based experiment.Social science & medicine (1982) · 2022Trial
- From memory clinics to Brain Health Services: implications for older adults and the future of cognitive care in Europe.European geriatric medicine · 2026Article
- Patient and representative experience after amyloid PET/CT in a real-world memory clinic: a mixed-methods observational study.EJNMMI reports · 2026Article
- Just Semantics? How Diagnostic Criteria Influence Physician-Patient Narratives in Alzheimer's Disease.Neuro-degenerative diseases · 2026Article
- Examining the Decision to Take a Dementia Risk Test: Considerations for Privacy in Screening At-Home.Dementia and geriatric cognitive disorders · 2026Article
- Willingness and barriers to blood-based biomarker testing of Alzheimer's disease in the general population in the Czech Republic.Alzheimer's research & therapy · 2026Article
- Long-term impact of disclosing amyloid PET results to individuals with subjective cognitive decline.Alzheimer's research & therapy · 2026Article
- Amyloid Imaging and APOE Genotype Disclosure and Short-Term Psychological Distress.JAMA network open · 2026Article
- Health Behavior of Adults Without Cognitive Impairment After Receiving Amyloid-β PET Results.JAMA network open · 2025Article
- Biomarker-Driven Diagnosis in Neurocognitive Disorders: A Clinician's Perspective on the Risks of Reductionism.Neurology. Clinical practice · 2025Article
- Return of research results across the Alzheimer's Disease Research Centers network.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Anticipated Responses to Genetic Testing for Alzheimer's Disease Susceptibility among Latinos in Northern Manhattan.Journal of community health · 2025Article
- Emotional response to amyloid beta status disclosure among research participants at high dementia risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Biomarkers do not paint the whole picture: The role of clinical expertise and advanced neuroimaging for Alzheimer's disease diagnosis.Journal of Alzheimer's disease : JAD · 2025Article
- Communicating the risk of dementia: a scoping review.BMJ neurology open · 2025Article
- Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
importanceClinical guidelines currently recommend against amyloid imaging for cognitively unimpaired persons. The goal of Alzheimer's disease (AD) prevention, together with advances in understanding the pathophysiology of AD, however, has led to trials testing drugs in cognitively unimpaired persons who show evidence of AD biomarkers. Assuming the eventual success of such trials, millions of patients will be affected. There is a need to understand the effects of biomarker disclosure on those individuals.
designThe Study of Knowledge and Reactions to Amyloid Testing (SOKRATES) involved 2 semi-structured telephone interviews with individuals who received amyloid PET scan results as part of screening for research participation. Post-disclosure interviews were conducted at 4 to 12 weeks and again 1 year later. Data were collected from November 5, 2014 to November 30, 2016. Interviews were transcribed and coded in NVivo 12.0.
participants80 adults aged 65 and older: 50 who received "elevated" and 30 who received "not-elevated" amyloid PET scan results. MAIN OUTCOMES: Interviews examined four domains: (1) comprehension of the amyloid PET scan result; (2) implications of the result for sense of self, memory, and future; (3) sharing of results with others; and (4) AD risk-reduction behaviors.
resultsParticipants who received an elevated amyloid PET scan result viewed the result as more serious and sensitive than other medical test results given its unique implications for identity, self-determination, and stigma. In contrast, participants who received a not-elevated amyloid PET scan result described feeling relief and reinterpreted perceived memory impairments as normal aging. Participants with elevated amyloid reported contemplating and making more changes to health behaviors and future plans than their peers with not-elevated amyloid.
conclusionsClinical practice in the diagnosis and treatment of persons with preclinical AD, a stage of the disease defined by the presence of biomarkers in the absence of cognitive impairment, will need to address matters of identity, stigma, and life-planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.